<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158299</url>
  </required_header>
  <id_info>
    <org_study_id>Clinical trail003</org_study_id>
    <nct_id>NCT02158299</nct_id>
  </id_info>
  <brief_title>Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer</brief_title>
  <official_title>Contrast The Role of Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <brief_summary>
    <textblock>
      After Axillary lymphadenectomy for breast cancer there are not few patients showed seroma
      formation and it can not be ignored.Investigators aimed to study two new methods of
      application of Microfibrillar Collagen Hemostat Flour and OK-432 to reduce seroma formation
      and to verify the efficacy and safety of these two applications.Try to prove them as
      beneficial supplements for axillary lymphadenectomy of breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective,randomized analysis of breast-conserving surgery or mastectomy plus axillary
      lymphadenectomy for those patients with sentinel node positive using Microfibrillar Collagen
      Hemostat Flour 、 OK-432 or using nothing in equal probability.Up to 12 months,a total of 180
      will be recruited in plan.During the operation and after the axillary
      lymphadenectomy，according the arms，Investigators put Microfibrillar Collagen Hemostat
      Flour（avitene）、 OK-432（Sapylin） or nothing into patients axillary wounds。And Investigators
      will the statistical significance of these three arms that the postoperative drainage
      magnitude and duration.Also the complications associated with axillary lymphadenectomy will
      be studied.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative drainage magnitude</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the drainage</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The complications of seroma formation</measure>
    <time_frame>up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Drainage</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avitene</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapylin</intervention_name>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>axillary drainage</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>reexamine</intervention_name>
    <arm_group_label>Avitene,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Sapylin,Drainaging,reexamine</arm_group_label>
    <arm_group_label>Drainaging,reexamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients volunteered for the study and signed informed consent；

          2. Preoperative biopsy or intraoperative sentinel lymph node biopsy confirmed axillary
             lymph node metastasis and need axillary lymphadenectomy

          3. No penicillin allergy

          4. No blood system diseases

          5. No rheumatic heart disease

          6. No history or family history of asthma

          7. No history of axillary surgery

        Exclusion Criteria:

          1. A history of severe hypertension

          2. A history of diabetes

          3. Undergoing anticoagulant therapy or anticoagulant therapy drug withdrawal less than a
             year

          4. BMI&gt;30

          5. Can not accept telephone follow-up or can not go to the hospital for subsequent
             inspection treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Wei juan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Wei juan</last_name>
    <phone>+86-20-34071157</phone>
    <email>13560328074@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Jing hua</last_name>
      <phone>+86-13560328074</phone>
      <email>jinghua87@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhao Jing hua</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jia Weijuan</investigator_full_name>
    <investigator_title>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

